In an interview with Medtech Insight, Dexcom’s COO Jake Leach and Adrian Gut, senior director international access, discuss the company’s global expansion, the role of AI in diabetes management, the challenges of securing reimbursement, and how regulators are influencing the future of CGM technology.
In this in-depth conversation, they discuss the challenges of expanding Dexcom’s global footprint, the company’s reimbursement strategy, and the evolving role of regulators in fostering innovation.
Key Takeaways
While countries like France offer full reimbursement for CGM users, many healthcare systems still lag. Dexcom is working with policymakers, clinicians, and advocacy groups to expand coverage globally.
Continuous glucose monitoring (CGM) technology has transformed diabetes management, enabling real-time tracking of glucose levels and empowering individuals to make informed health decisions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.
Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.
Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.
